Meperidine — known by its historic brand name Demerol — was once one of the most widely used opioid analgesics in American medicine. For decades it was the "go-to" injectable opioid in emergency rooms, labor and delivery wards, and post-operative care. Today, meperidine has fallen dramatically out of favor and is now considered a second-line opioid at best — largely supplanted by safer, better-tolerated alternatives. Understanding why meperidine's reputation has declined so significantly reveals important lessons about opioid pharmacology, drug interactions, and patient safety.
What Is Meperidine?
Meperidine (INN) or pethidine (international name) is a fully synthetic opioid analgesic first synthesized in Germany in 1939. It was initially developed as an anticholinergic (antispasmodic) drug and its opioid properties were discovered incidentally. For several decades in the mid-20th century, meperidine was the most commonly administered injectable opioid in American hospitals — partly due to a mistaken belief that it was less addictive than morphine (it is not) and had unique advantages for specific clinical situations (most of which are not well supported by evidence).
Meperidine is a Schedule II controlled substance. Brand name: Demerol. Available as: oral tablets (50 mg, 100 mg), oral syrup (50 mg/5 mL), and injectable solution (10–100 mg/mL). Generic meperidine hydrochloride is also available.
How Meperidine Works
Meperidine is a full agonist at mu-opioid receptors, producing analgesia, sedation, euphoria, and respiratory depression through the same mechanism as all opioid analgesics. However, meperidine has several unique pharmacological properties that distinguish it from other opioids:
- Local anesthetic activity: Meperidine has significant sodium channel blocking (local anesthetic) properties — the only opioid to have this characteristic. This explains some historic uses (epidural meperidine) and some unique side effects.
- Anticholinergic activity: Meperidine has atropine-like anticholinergic effects — more than any other opioid. This causes tachycardia (fast heart rate) rather than the bradycardia seen with morphine, dry mouth, urinary retention, and blurred vision.
- Serotonin reuptake inhibition: Meperidine inhibits serotonin reuptake, creating dangerous interactions with serotonergic drugs.
- Toxic metabolite — normeperidine: The most clinically important pharmacological feature. Normeperidine is a CNS excitatory metabolite formed when meperidine is metabolized by the liver. Unlike the parent drug, normeperidine causes neuroexcitation: anxiety, tremors, myoclonus (muscle jerking), and — at high concentrations — grand mal seizures.
The Normeperidine Problem: Why Meperidine Is Dangerous
Normeperidine is the primary reason meperidine is no longer recommended for most clinical situations. Key facts about this toxic metabolite:
- Normeperidine has a half-life of 15–20 hours — much longer than meperidine itself (3–5 hours). This means normeperidine accumulates with repeated dosing even when meperidine itself is cleared normally.
- Normeperidine is renally excreted. In patients with renal impairment, normeperidine accumulates dramatically, dramatically increasing seizure risk.
- Naloxone does NOT reverse normeperidine toxicity — in fact, naloxone administration in a patient with normeperidine accumulation can worsen seizures by removing the concurrent opioid sedation that was partially masking the excitatory effects.
- Normeperidine seizures are therefore particularly dangerous and difficult to manage.
- Risk groups include: patients receiving meperidine for more than 48 hours, patients receiving high cumulative doses, patients with renal impairment, elderly patients, and those with hepatic failure.
When Is Meperidine Still Used?
Despite its declining popularity, meperidine retains some niche clinical applications:
Treatment of Rigors (Shivering)
Meperidine's kappa-opioid activity makes it uniquely effective for treating shaking chills (rigors) — such as those following blood transfusions, amphotericin B infusions, or post-anesthetic shivering. It is widely considered the most effective single drug for this indication. A single low IV dose (12.5–25 mg) typically terminates rigors within minutes. This remains one of the few situations where meperidine is still broadly recommended.
Procedural Pain in Specific Contexts
Meperidine is occasionally used for ERCP (endoscopic retrograde cholangiopancreatography) and other gastrointestinal procedures by practitioners who believe it causes less sphincter of Oddi spasm than other opioids — though evidence for this advantage is weak.
Obstetric Pain
Meperidine has been used for labor pain management in some contexts, though its use has declined substantially due to concerns about normeperidine accumulation in the neonate (neonatal meperidine metabolism is immature, leading to normeperidine accumulation and neonatal CNS depression and neurobehavioral changes lasting up to 72 hours).
Meperidine Dosage
| Indication | Dose | Route | Max Duration |
|---|---|---|---|
| Acute pain (moderate-severe) | 50–150 mg every 3–4 hrs | Oral/IM/IV | 48 hours maximum recommended |
| Rigors treatment | 12.5–25 mg single dose | IV slow push | Single dose |
| Procedural sedation | 25–100 mg | IV/IM | Single episode |
| Renal impairment | Avoid or single dose only | Any | Single dose maximum |
ISMP, the Joint Commission, and numerous hospital systems have removed meperidine from formularies or restricted it to single-dose use for rigors only. The WHO has removed meperidine from its Model List of Essential Medicines.
Dangerous Drug Interactions
- MAO inhibitors (contraindicated): The most severe interaction in pharmacology. Combining meperidine with MAOIs (phenelzine, tranylcypromine, linezolid, methylene blue) can cause a catastrophic serotonergic/excitatory reaction with hyperpyrexia (extremely high fever), rigidity, seizures, coma, and death. Even a single dose of meperidine in a patient on an MAOI can be fatal. A 14-day washout is required after stopping an MAOI.
- SSRIs and SNRIs: Meperidine's serotonin reuptake inhibition creates significant serotonin syndrome risk when combined with SSRIs, SNRIs, or other serotonergic medications.
- CYP3A4 inhibitors (azole antifungals, certain HIV drugs) — reduce meperidine metabolism; increase normeperidine accumulation risk
- Phenobarbital and phenytoin (enzyme inducers) — accelerate meperidine metabolism but also accelerate normeperidine formation
- Benzodiazepines and CNS depressants — additive respiratory depression
Side Effects of Meperidine
- Nausea and vomiting (prominent, especially with oral use)
- Tachycardia (fast heart rate) — from anticholinergic effects; unique among opioids
- Dry mouth, blurred vision (anticholinergic)
- Constipation (less than morphine)
- Sedation and dizziness
- Respiratory depression
- Normeperidine toxicity: anxiety, irritability, tremors, myoclonus, seizures
- Physical dependence and addiction risk
- Dysphoria and hallucinogenic effects at higher doses (more prominent than with other opioids)